Novartis reported successful phase 3 trial results for ianalumab, an antibody targeting BAFF-R, in patients with Sjögren’s syndrome. The drug demonstrated statistically significant reductions in disease activity with a favorable safety profile, marking the first global phase 3 success in this chronic autoimmune condition. Novartis plans to seek regulatory approval based on these results, offering potential for the first targeted therapy addressing this condition’s unmet medical needs.